Transplant Institute

Boston, MA, United States

Transplant Institute

Boston, MA, United States

Time filter

Source Type

LEXINGTON, Mass., May 19, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc., (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health and deliver a strong economic return to healthcare institutions, announced today the company, in collaboration with LabRoots, will host a webinar on May 22, 2017, beginning at 10:00 a.m. PT/1:00 p.m. ET. The webinar will be hosted by renowned clinical expert Dr. George Alangaden, Senior Staff Physician Director, Transplant Infectious Diseases, Medical Director of Infection Prevention, Henry Ford Hospital System (HFHS). Dr. Alangaden will discuss how HFHS implemented T2MR® and the T2Candida Panel as part of their sepsis protocol for the management of candidemia. He will also share the positive impact T2MR and T2Candida has had at HFHS on patient length of stay and antifungal use. To read more on this free webinar, learn about the continuing education credits offered, or to register, click here. Dr. Alangaden received his medical degree from the University of Bombay and has since completed post-graduate training in India, the United Kingdom and the United States. Dr. Alangaden is the Director of Transplant Infectious Diseases and Director of Infection Control and Prevention at Henry Ford Hospital and Transplant Institute. Dr. Alangaden's research interest lies in the epidemiology and outcomes of infections in immunocompromised patients and transplant recipients. He is also involved and well-published in the areas of research related to tuberculosis and nosocomial infections, especially Clostridium difficile. T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With the FDA-cleared T2Dx® Instrument and T2Candida Panel targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance technology, or T2MR, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of patient sample types, including whole blood. For more information, please visit www.t2biosystems.com. LabRoots is the leading scientific social networking website and producer of educational virtual events and webinars. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning and is a primary source for current scientific news, webinars, virtual conferences and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.


LEXINGTON, Mass., May 19, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc., (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health and deliver a strong economic return to healthcare institutions, announced today the company, in collaboration with LabRoots, will host a webinar on May 22, 2017, beginning at 10:00 a.m. PT/1:00 p.m. ET. The webinar will be hosted by renowned clinical expert Dr. George Alangaden, Senior Staff Physician Director, Transplant Infectious Diseases, Medical Director of Infection Prevention, Henry Ford Hospital System (HFHS). Dr. Alangaden will discuss how HFHS implemented T2MR® and the T2Candida Panel as part of their sepsis protocol for the management of candidemia. He will also share the positive impact T2MR and T2Candida has had at HFHS on patient length of stay and antifungal use. To read more on this free webinar, learn about the continuing education credits offered, or to register, click here. Dr. Alangaden received his medical degree from the University of Bombay and has since completed post-graduate training in India, the United Kingdom and the United States. Dr. Alangaden is the Director of Transplant Infectious Diseases and Director of Infection Control and Prevention at Henry Ford Hospital and Transplant Institute. Dr. Alangaden's research interest lies in the epidemiology and outcomes of infections in immunocompromised patients and transplant recipients. He is also involved and well-published in the areas of research related to tuberculosis and nosocomial infections, especially Clostridium difficile. T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With the FDA-cleared T2Dx® Instrument and T2Candida Panel targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance technology, or T2MR, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of patient sample types, including whole blood. For more information, please visit www.t2biosystems.com. LabRoots is the leading scientific social networking website and producer of educational virtual events and webinars. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning and is a primary source for current scientific news, webinars, virtual conferences and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.


LEXINGTON, Mass., May 19, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc., (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health and deliver a strong economic return to healthcare institutions, announced today the company, in collaboration with LabRoots, will host a webinar on May 22, 2017, beginning at 10:00 a.m. PT/1:00 p.m. ET. The webinar will be hosted by renowned clinical expert Dr. George Alangaden, Senior Staff Physician Director, Transplant Infectious Diseases, Medical Director of Infection Prevention, Henry Ford Hospital System (HFHS). Dr. Alangaden will discuss how HFHS implemented T2MR® and the T2Candida Panel as part of their sepsis protocol for the management of candidemia. He will also share the positive impact T2MR and T2Candida has had at HFHS on patient length of stay and antifungal use. To read more on this free webinar, learn about the continuing education credits offered, or to register, click here. Dr. Alangaden received his medical degree from the University of Bombay and has since completed post-graduate training in India, the United Kingdom and the United States. Dr. Alangaden is the Director of Transplant Infectious Diseases and Director of Infection Control and Prevention at Henry Ford Hospital and Transplant Institute. Dr. Alangaden's research interest lies in the epidemiology and outcomes of infections in immunocompromised patients and transplant recipients. He is also involved and well-published in the areas of research related to tuberculosis and nosocomial infections, especially Clostridium difficile. T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With the FDA-cleared T2Dx® Instrument and T2Candida Panel targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance technology, or T2MR, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of patient sample types, including whole blood. For more information, please visit www.t2biosystems.com. LabRoots is the leading scientific social networking website and producer of educational virtual events and webinars. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning and is a primary source for current scientific news, webinars, virtual conferences and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.


LEXINGTON, Mass., May 19, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc., (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health and deliver a strong economic return to healthcare institutions, announced today the company, in collaboration with LabRoots, will host a webinar on May 22, 2017, beginning at 10:00 a.m. PT/1:00 p.m. ET. The webinar will be hosted by renowned clinical expert Dr. George Alangaden, Senior Staff Physician Director, Transplant Infectious Diseases, Medical Director of Infection Prevention, Henry Ford Hospital System (HFHS). Dr. Alangaden will discuss how HFHS implemented T2MR® and the T2Candida Panel as part of their sepsis protocol for the management of candidemia. He will also share the positive impact T2MR and T2Candida has had at HFHS on patient length of stay and antifungal use. To read more on this free webinar, learn about the continuing education credits offered, or to register, click here. Dr. Alangaden received his medical degree from the University of Bombay and has since completed post-graduate training in India, the United Kingdom and the United States. Dr. Alangaden is the Director of Transplant Infectious Diseases and Director of Infection Control and Prevention at Henry Ford Hospital and Transplant Institute. Dr. Alangaden's research interest lies in the epidemiology and outcomes of infections in immunocompromised patients and transplant recipients. He is also involved and well-published in the areas of research related to tuberculosis and nosocomial infections, especially Clostridium difficile. T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With the FDA-cleared T2Dx® Instrument and T2Candida Panel targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance technology, or T2MR, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of patient sample types, including whole blood. For more information, please visit www.t2biosystems.com. LabRoots is the leading scientific social networking website and producer of educational virtual events and webinars. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning and is a primary source for current scientific news, webinars, virtual conferences and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.


LEXINGTON, Mass., May 19, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc., (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health and deliver a strong economic return to healthcare institutions, announced today the company, in collaboration with LabRoots, will host a webinar on May 22, 2017, beginning at 10:00 a.m. PT/1:00 p.m. ET. The webinar will be hosted by renowned clinical expert Dr. George Alangaden, Senior Staff Physician Director, Transplant Infectious Diseases, Medical Director of Infection Prevention, Henry Ford Hospital System (HFHS). Dr. Alangaden will discuss how HFHS implemented T2MR® and the T2Candida Panel as part of their sepsis protocol for the management of candidemia. He will also share the positive impact T2MR and T2Candida has had at HFHS on patient length of stay and antifungal use. To read more on this free webinar, learn about the continuing education credits offered, or to register, click here. Dr. Alangaden received his medical degree from the University of Bombay and has since completed post-graduate training in India, the United Kingdom and the United States. Dr. Alangaden is the Director of Transplant Infectious Diseases and Director of Infection Control and Prevention at Henry Ford Hospital and Transplant Institute. Dr. Alangaden's research interest lies in the epidemiology and outcomes of infections in immunocompromised patients and transplant recipients. He is also involved and well-published in the areas of research related to tuberculosis and nosocomial infections, especially Clostridium difficile. T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With the FDA-cleared T2Dx® Instrument and T2Candida Panel targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance technology, or T2MR, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of patient sample types, including whole blood. For more information, please visit www.t2biosystems.com. LabRoots is the leading scientific social networking website and producer of educational virtual events and webinars. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning and is a primary source for current scientific news, webinars, virtual conferences and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.


SAN DIEGO, CA--(Marketwired - October 24, 2016) - Targazyme Inc., a clinical stage biopharmaceutical company developing novel enzyme technologies and products to improve clinical efficacy and cost of care outcomes for a variety of cell therapies including stem cell transplantation, immunotherapy, gene therapy and regenerative medicine, announced today that the U.S. Food and Drug Administration (FDA) has granted IND Clearance to begin enrolling patients in a Phase II clinical study to evaluate the safety and efficacy of TZ101-fucosylated bone marrow stem cells from haplo-identical donors in cancer patients. The transplantation of blood-forming stem cells from bone marrow is an accepted treatment to restore the body's ability to make blood and immune cells and is a treatment for various cancers like leukemia, lymphoma and some types of anemia. Recent medical advances have made possible the use of a haploidentical donor who is usually a 50% match to the recipient. Targazyme's product (TZ101) has the potential to improve the outcomes of this lifesaving treatment by improving the ability of TZ101 treated stem cells to home, adhere and engraft into the bone marrow, accelerating hematopoietic recovery, reducing both opportunistic infections and ICU/hospital stay for cancer patients undergoing the haplo-identical transplants. "Enhancing bone marrow stem cell engraftment with a product like TZ101 will improve clinical outcomes for patients with serious, life-threatening cancers and other disorders for which hematopoietic stem cell transplant is prescribed," said Dr. Gheath Alatrash, Assistant Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. "This FDA IND clearance for a phase 2 TZ101 haplo-identical transplant study is an important clinical milestone to help us drive towards our initial target product label of accelerating hematopoietic recovery post hematopoietic stem cell transplantation" said Lynnet Koh, Chief Executive Officer of Targazyme. "This clinical study builds on available clinical data that TZ101 improves time to absolute neutrophil count and platelet recovery in patients undergoing hematopoietic stem cell transplants, and together, with our second product TZ102, provides proof of concept that our pipeline of products are enabling technologies for improving efficacy outcomes for various cells such as T cells, natural killer cells, and hematopoietic, cardiac and neural stem cells, that are used to prevent and treat a variety of different diseases for which there is a high unmet medical need." Targazyme Inc. is a San Diego-based, clinical-stage biopharmaceutical company developing novel enzyme-based platform technologies and products to improve clinical efficacy and cost of care outcomes for cell therapy, immunotherapies for autoimmune diseases and cancer, stem cell transplantation, gene therapy and regenerative medicine. The Company's clinical-grade fucosyltransferase enzymes and small molecule products (TZ101 and TZ102) are off-the-shelf biologic products used at the point-of-care to treat therapeutic cells immediately before infusion into the patient using a simple procedure that is easily incorporated into existing medical practice. The Company has received worldwide patents, multiple FDA orphan drug designations, has an open investigational new drug application (IND) with multiple ongoing clinical studies and a Phase 3 Special Protocol Assessment (SPA) with the FDA. Targazyme's fucosylation technology has received numerous medical and scientific awards from institutions such as NIH, NCI, US Treasury, CPRIT, ETF, OCAST, JDRF, Leukemia, Lymphoma Society. Targazyme has partnerships and collaborations with Kyowa Hakko Kirin and Florida Biologix, as well as various medical research institutions including The University of Texas M.D. Anderson Cancer Center, Oklahoma Medical Research Foundation, Texas Transplant Institute, Case Western/University Hospitals, Scripps Hospitals, Fred Hutchinson Cancer Research Center, University of California Los Angeles Medical Center, Stanford University Medical Center, University of Minnesota Medical Center, University of California San Diego Medical Center, Sanford-Burnham Medical Research Institute, Indiana University, Memorial Sloan Kettering Cancer Center, and New York Blood Center. Learn more at http://www.targazyme.com.


News Article | April 11, 2016
Site: motherboard.vice.com

The promise of immortality is core to many religions, but it’s rarely as literal as it is at The Church of Perpetual Life, a zealous house of worship in Hollywood, Florida whose members have decided they don’t want to die. "We are fighting against involuntary death, and view immortality as the ultimate solution to every problem mankind faces,” said Bill Faloon, one of the church’s founders. His parishioners call themselves “immortalists.” Other monikers include transhumanists, “longevity enthusiasts,” and “people who really are committed to the anti-aging concept.” Whatever they call themselves, they all share one thing in common: They believe that science and technology will find a way for humans to live forever on Earth. Motherboard’s Claire Evans visited the church and spent time with Faloon, who also cofounded the Life Extension Foundation Inc., which sells a variety of nutritional supplements that promise to do everything from protecting against eyesight degeneration to promoting cell regeneration. The Foundation says its primary goal is to fund research into anti-aging science. Forever Young, a short documentary produced by Evans, Jaimie Sanchez, and Motherboard, explores the psychology of the church’s members, the history of transhumanism and anti-aging, and the reaction of the mainstream medical community to some of these ideas. Gerontology expert Aubrey Grey, transhumanist and Sirius XM founder Martine Rothblatt, and Dr. Dinarine Maharaj of the South Florida Stem Cell Transplant Institute also make an appearance in the film. The people Evans spoke to, including Faloon, seem genuine in their quest for eternal life. However, it’s hard to overlook the fact that the church was formed after the Life Extension Foundation had its tax-exempt status revoked by the IRS. Is the Church of Perpetual Life a fellowship of purist transhumanist devotees, or a front for shilling vitamins? Is its promise of immortality a scam that draws in wishful thinkers, or is it actually possible that one day, humans might conquer death? "Sometimes it's very difficult to draw a line about what seems crazy and what doesn't seem crazy,” Evans said, “because crazier things have happened. We went to the Moon. Where do you draw the line and say, ‘oh that's really science fiction, that's never going to happen?’"


Tamimi T.I.A.-R.,Digestive Disease Institute | Elgouhari H.M.,Transplant Institute | Alkhouri N.,Cleveland Clinic | Yerian L.M.,Cleveland Clinic | And 5 more authors.
Journal of Hepatology | Year: 2011

Background & Aims: The extrinsic death receptor-mediated pathway of apoptosis is involved in nonalcoholic steatohepatitis (NASH) development. Our aims were to create and validate a noninvasive prediction model for NASH diagnosis based on specific circulating markers of apoptosis. Methods: Our initial cohort consisted of 95 consecutive patients undergoing a liver biopsy for clinically suspected NASH. Blood was obtained from each patient at the time of liver biopsy. Plasma caspase 3 generated cytokeratin-18 fragments (CK-18), soluble Fas (sFas), and soluble Fas ligand (sFasL) were measured. Histology was assessed by an experienced hepatopathologist. The validation cohort consisted of 82 consecutive patients that underwent liver biopsy at the time of bariatric surgery. Results: Patients with NASH had significantly higher levels of CK-18 and sFas than patients in the "not NASH" group [median (25th, 75th percentile): 508 (280, 846) U/L versus 176 (131, 224) U/L (p <0.001), and 11.8 (7.8, 12.5) ng/ml versus 5.9 (4.8, 8.3) ng/ml (p <0.001), respectively]. A significant positive correlation was revealed between the apoptosis markers and liver histopathology independent of other metabolic factors. A prediction model was generated including CK-18 fragments and sFas levels that showed an AUC of 0.93 and 0.79 in the initial and validation cohorts, respectively. A cutoff value using this model predicted NASH with a sensitivity and specificity of 88% and 89%, respectively. Conclusions: Quantification of circulating levels of two apoptotic markers accurately predicts the presence of NASH, supporting the potential usefulness of these markers in clinical practice for noninvasive diagnosis of NASH. © 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.


Hardinger K.L.,University of Missouri | Hutcherson T.,University of Missouri | Preston D.,University of Missouri | Murillo D.,Transplant Institute
Pharmacotherapy | Year: 2012

Study Objective. To determine the influence of pill burden and drug cost on outcomes after renal transplantation. Design. Retrospective medical record review. Setting. Kidney and pancreas transplantation center. Patients. Sixty-eight adults who underwent kidney or kidney-pancreas transplantation during 2007. Measurements and Main Results. The median pretransplantation pill burden was 15 pills/day, which increased to 25 pills/day at 1 month after transplantation and returned to 16 pills/day by 1 year after transplantation. Pretransplantation pill burden was lower than the burden at 1, 3, 6, 12, and 24 months after transplantation (p<0.05). The mean pretransplantation drug cost of $1918/month was lower than the cost at 1 month after transplantation ($2564/mo, p=0.04) but was similar thereafter. Higher pretransplantation pill burden was associated with increased serum creatinine concentration at 6 months after transplantation (r=0.288, p=0.017). Higher pill burdens at 1 month (r=0.364, p=0.002), 3 months (r=0.332, p=0.006), and 6 months (r=0.374, p=0.002) were associated with increased 3-month serum creatinine concentration. Higher drug costs were associated with increased serum creatinine concentrations throughout the study. Conclusion. Higher pretransplantation pill burden and higher drug cost may be associated with poor renal function after transplantation. Further study addressing factors associated with nonadherence is needed. Copyright © 1999-2012 John Wiley & Sons, Inc.


Singhal A.,Transplant Institute | Kanagala R.,Transplant Institute | Jalil S.,Transplant Institute | Wright H.I.,Transplant Institute | Kohli V.,Transplant Institute
Annals of Hepatology | Year: 2011

Chronic HBV infection is a dynamic state of interaction between HBV, hepatocytes, and the immune system of the host. A series of reactivation flares and remissions may occur due to multiple causes. Among them, spontaneous reactivation and immunosuppressive drugs including steroids or cancer chemotherapy are well known. This is due to immune-mediated destruction of HBV-expressing cells following withdrawal of immunosuppressive effect. Few cases have been reported in females during postpartum period. We report a case of fulminant hepatic failure during pregnancy in a previously unrecognized hepatitis B positive female requiring emergent liver transplantation.

Loading Transplant Institute collaborators
Loading Transplant Institute collaborators